Envestnet Asset Management Inc Biocryst Pharmaceuticals Inc Transaction History

Envestnet Asset Management Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	SELL	$4.13 - $6.79 $30,809 - $50,653	-7,460 Reduced 41.92%	10,335 $63,000
Q1 2024 May 13, 2024	BUY	$4.89 - $7.65 $87,017 - $136,131	17,795 New	17,795 $90,000
Q3 2018 Nov 14, 2018	SELL	$5.52 - $7.99 $656 - $950	-119 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	119	119 $1,000

279

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Envestnet Asset Management Inc with notifications on news.